Azzad Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $613K | Buy |
984
+3
| +0.3% | +$2.04K | 0.05% | 287 |
|
|
2026
Q1 | $758K | Buy |
+981
| New | +$751K | 0.08% | 257 |
|
|
2022
Q4 | – | Sell |
-3,093
| Closed | -$1.97M | – | 372 |
|
|
2022
Q3 | $1.97M | Sell |
3,093
-2,000
| -39% | -$1.26M | 0.2% | 170 |
|
|
2022
Q2 | $3.09M | Buy |
5,093
+2,555
| +101% | +$1.66M | 0.31% | 112 |
|
|
2022
Q1 | $1.77M | Sell |
2,538
-789
| -24% | -$499K | 0.26% | 154 |
|
|
2021
Q4 | $2.1M | Buy |
3,327
+32
| +1% | +$19.7K | 0.28% | 140 |
|
|
2021
Q3 | $1.99M | Buy |
3,295
+74
| +2% | +$45.9K | 0.29% | 138 |
|
|
2021
Q2 | $1.8M | Sell |
3,221
-100
| -3% | -$50.7K | 0.27% | 155 |
|
|
2021
Q1 | $1.57M | Buy |
3,321
+233
| +8% | +$113K | 0.26% | 158 |
|
|
2020
Q4 | $1.49M | Sell |
3,088
-3
| -0.1% | -$1.62K | 0.27% | 147 |
|
|
2020
Q3 | $1.73M | Buy |
3,091
+567
| +22% | +$344K | 0.36% | 110 |
|
|
2020
Q2 | $1.57M | Sell |
2,524
-583
| -19% | -$331K | 0.37% | 97 |
|
|
2020
Q1 | $1.52M | Sell |
3,107
-2,437
| -44% | -$1.01M | 0.44% | 75 |
|
|
2019
Q4 | $2.71M | Buy |
5,544
+56
| +1% | +$18.8K | 0.32% | 108 |
|
|
2019
Q3 | $2.4M | Buy |
+5,488
| New | +$1.62M | 0.3% | 118 |
|
|
2017
Q2 | – | Sell |
-652
| Closed | -$253K | – | 305 |
|
|
2017
Q1 | $253K | Hold |
652
| – | – | 0.1% | 242 |
|
|
2016
Q4 | $239K | Hold |
652
| – | – | 0.1% | 225 |
|
|
2016
Q3 | $262K | Hold |
652
| – | – | 0.11% | 227 |
|
|
2016
Q2 | $228K | Hold |
652
| – | – | 0.1% | 231 |
|
|
2016
Q1 | $235K | Sell |
652
-1
| -0.2% | -$412 | 0.1% | 226 |
|
|
2015
Q4 | $354K | Sell |
653
-2
| -0.3% | -$1.08K | 0.17% | 193 |
|
|
2015
Q3 | $305K | Hold |
655
| – | – | 0.16% | 208 |
|
|
2015
Q2 | $334K | Sell |
655
-855
| -57% | -$417K | 0.17% | 211 |
|
|
2015
Q1 | $682K | Hold |
1,510
| – | – | 0.33% | 126 |
|
|
2014
Q4 | $620K | Sell |
1,510
-953
| -39% | -$375K | 0.33% | 123 |
|
|
2014
Q3 | $888K | Hold |
2,463
| – | – | 0.51% | 50 |
|
|
2014
Q2 | $696K | Sell |
2,463
-525
| -18% | -$156K | 0.42% | 98 |
|
|
2014
Q1 | $897K | Buy |
2,988
+37
| +1% | +$11.4K | 0.59% | 32 |
|
|
2013
Q4 | $812K | Buy |
2,951
+43
| +1% | +$12.4K | 0.59% | 44 |
|
|
2013
Q3 | $910K | Hold |
2,908
| – | – | 0.75% | 20 |
|
|
2013
Q2 | $694K | Buy |
+2,908
| New | +$677K | 0.6% | 42 |
|
Other funds holding REGN
Azzad Asset Management's REGN Position: Q2 2026 in Review
Azzad Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 0.31% in Q2 2026, buying an estimated $2.04K and bringing the position to 984 shares worth $613K. The position accounts for 0.05% of the portfolio, ranked #287.
Azzad Asset Management first reported a position in REGN in Q2 2013 and has held it in 31 quarters since. The position peaked at $3.09M in Q2 2022. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Azzad Asset Management held 984 shares of Regeneron Pharmaceuticals worth $613K as of Q2 2026.
- Azzad Asset Management bought 3 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.04K.
- Regeneron Pharmaceuticals made up 0.05% of Azzad Asset Management's portfolio in Q2 2026, its #287 holding.
- Azzad Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 31 quarters since.
- Azzad Asset Management's Regeneron Pharmaceuticals position peaked at $3.09M in Q2 2022.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Azzad Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.